SURVYR

QDEL

QuidelOrtho Corporation
$13.59
−$0.18 (1.31%)Oct 27 close
Health CareS&P 600 CompareTechnicals
1M3M6M1Y2Y
-66%-45%-23%-1%+21%Oct 2025Oct 2026Apr 202652w high $35.5852w low $9.92
QDELSPY
Wall St. Highest PT $20.00 (+47.2%) Wall St. Avg PT $14.67 (+7.9%)
$10$16$23$29$35POC $14Hi $20Avg $15
Underwater Drawdown %Max DD -71.8%Current -61.6%
0.0%-71.8%
Relative Strength vs SPY-67.4% vs SPYUnderperforming
+90%0%-90%
1W
−$0.62 (4.36%)
1M
+$2.65 (24.22%)
3M
−$3.08 (18.48%)
6M
+$1.57 (13.06%)
YTD
−$14.97 (52.42%)
1Y
−$15.89 (53.90%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Hold
3 analysts · mean score 2.67
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$13.59
Average target$14.67
+$1.08 (+7.9%) upsideaverage target vs current price
CurrentAverageMedian
Low$12.00
Median$14.67
High$20.00
12-month Wall Street target range
Recent analyst rating changes · 8
Reiterated
2026-07-08 · Citigroup reiterated Neutral on QDEL
Reiterated
2026-07-01 · JP Morgan reiterated Underweight on QDEL
Downgrade
2026-05-07 · Jefferies downgraded QDEL from Buy to Hold
Reiterated
2026-05-06 · Citigroup reiterated Neutral on QDEL
Reiterated
2026-04-10 · UBS reiterated Neutral on QDEL
Reiterated
2026-02-12 · Citigroup reiterated Neutral on QDEL
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$974.5M
P/E (next 12 months, estimated)10.0
52-week range$9.92 – $35.58
Revenue growth (latest quarter vs a year ago)+2.8%
Dividend yieldNo dividend
Analyst consensusHold (3)
Average analyst price target$14.67 (+8%)

What they do

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients.

Healthcare · Medical Devices
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
1st percentile in sector
F
12-1 return: -60.9%
Percentile within its GICS sector across the S&P 1500.
Growth
21st percentile in sector
D
Revenue growth (YoY): +2.8%
Percentile within its GICS sector across the S&P 1500.
Value
89th percentile in sector
A
Forward E/P: 11.1% · EBITDA/EV: 12.6%
Percentile within its GICS sector across the S&P 1500.
Profitability
4th percentile in sector
F
Profit margin: -39.2% · Return on equity: -45.9%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

QDEL earningsNext report in 6 days
Next report · quarter Sep 2026
Tue Nov 3, 2026After the close
EPS consensus$0.18 range $0.18–$0.18
Revenue consensus$627.7M 3 analysts
Last 4 quarters · EPS vs estimate
Aug 6, 2026$0.13est -$0.05+374.6%Above estimates
May 5, 2026-$0.04est $0.36−111.2%Below estimates
Feb 11, 2026$0.46est $0.42+8.8%Above estimates
Nov 5, 2025$0.80est $0.47+71.6%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-21 01:35:38 ET
24-1125-0225-0525-0825-1126-0226-0526-08-0.050.85
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$630.9M+2.8%
2026-03-31$619.8M–
2025-12-31$723.6M–
2025-09-30$699.9M–
2025-06-30$613.9M–

News & catalysts

More news
QuidelOrtho to Report Third Quarter 2026 Financial Results on November 3, 2026
PR Newswire · Oct 20
Rating changes
Reiterated
2026-07-08 · Citigroup reiterated Neutral on QDEL
Reiterated
2026-07-01 · JP Morgan reiterated Underweight on QDEL
Downgrade
2026-05-07 · Jefferies downgraded QDEL from Buy to Hold
Reiterated
2026-05-06 · Citigroup reiterated Neutral on QDEL
Reiterated
2026-04-10 · UBS reiterated Neutral on QDEL
Reiterated
2026-02-12 · Citigroup reiterated Neutral on QDEL

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-21 01:35:38 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026